Last updated on March 2019

Study of Irinotecan Liposome Injection (ONIVYDE ) in Patients With Small Cell Lung Cancer


Brief description of study

A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based First-Line Therapy

The study will be conducted in two parts:

  1. Dose determination of irinotecan liposome injection
  2. A randomized, efficacy study of irinotecan liposome injection versus topotecan

Detailed Study Description

The study will be conducted in two parts:

Part 1: Open-label dose finding study of irinotecan liposome injection. Approximately 24-36 patients will be enrolled.

Part 1 Primary Objectives:

  • Describe the safety and tolerability of irinotecan liposome injection monotherapy administered every 2 weeks
  • Determine the optimal irinotecan liposome injection monotherapy dose for Part 2 of this study

Part 2: A randomized, efficacy study of irinotecan liposome injection versus IV topotecan.

Approximately 450 patients will be enrolled in part 2.

Part 2 objectives: Detailed in the Primary & Secondary outcome measure sections.

Clinical Study Identifier: NCT03088813

Contact Investigators or Research Sites near you

Start Over

Centre Hospitalier de Saint-Quentin

Saint-Quentin, France
1.22miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.